A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Ondansetron (Primary) ; Palonosetron (Primary)
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use

12 Dec 2016 Status changed to completed.
16 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016 as reported by ClinicalTrial.gov record.
16 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com